Increased sales of AHIT® and urexent®
For AHIT® and urexent®, FBM-PHARMA has been able to increase its sales revenues in recent months due to targeted addressing of already active medical doctors.
News
FBM-PHARMA: Preparations for autologous serum eye drops are on schedule
Negotiations with collection centres in North Rhine-Westphalia and Saarland are well advanced, the necessary agreements are in the final vote. Thus, the FBM PHAMRA can immediately leave their first footprint on the map with respect to the procurement of autologous blood and blood components for the production of autologous serum eye drops (ASAT).
Phase II study: second round of European funding
As planned, VCC Medical had submitted the application in the second round of funding scheduled for the end of October as part of the "Horizon 2020" program. However, the European Commission recently requested a further update of the submission documents, which the VCC Medical Group will implement as requested in the upcoming weeks.
Reniale®: Development of the Biomarker assays well advanced
A key element in improving Reniale® is to demonstrate the biological effectiveness of Reniale®.
Capital acquisition remains the focus of Vaccentis AG
While the scientific work on Reniale is being pursued within the limits of the company's financial capabilities, management's focus is on raising capital.